JP2014534196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534196A5 JP2014534196A5 JP2014535789A JP2014535789A JP2014534196A5 JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5 JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- rasagiline
- weight
- amount
- propargyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PETXFKWYHQOVRD-CYBMUJFWSA-N C#CCN([C@H]1c2ccccc2CC1)C=O Chemical compound C#CCN([C@H]1c2ccccc2CC1)C=O PETXFKWYHQOVRD-CYBMUJFWSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545422P | 2011-10-10 | 2011-10-10 | |
| US61/545,422 | 2011-10-10 | ||
| PCT/US2012/059356 WO2013055687A2 (en) | 2011-10-10 | 2012-10-09 | R(+)-n-formyl-propargyl-aminoindan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014534196A JP2014534196A (ja) | 2014-12-18 |
| JP2014534196A5 true JP2014534196A5 (enExample) | 2015-12-03 |
Family
ID=48042235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535789A Pending JP2014534196A (ja) | 2011-10-10 | 2012-10-09 | Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9346746B2 (enExample) |
| EP (1) | EP2766002A4 (enExample) |
| JP (1) | JP2014534196A (enExample) |
| KR (1) | KR20140090996A (enExample) |
| CN (1) | CN103874487A (enExample) |
| AR (1) | AR088297A1 (enExample) |
| AU (1) | AU2012323349A1 (enExample) |
| BR (1) | BR112014008555A2 (enExample) |
| CA (1) | CA2851276A1 (enExample) |
| EA (1) | EA201490761A1 (enExample) |
| HK (1) | HK1200315A1 (enExample) |
| IL (1) | IL231721A0 (enExample) |
| MX (1) | MX2014004308A (enExample) |
| WO (1) | WO2013055687A2 (enExample) |
| ZA (1) | ZA201403043B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EA016820B1 (ru) * | 2006-12-14 | 2012-07-30 | Тева Фармасьютикал Индастриз, Лтд. | Кристаллическое твердое основание разагилина |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| ES2389353T3 (es) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
| RS53504B1 (sr) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | Soli razagilina i njihovi farmaceutski preparati |
| US20110130466A1 (en) * | 2009-10-09 | 2011-06-02 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2939669A1 (en) * | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| AU2012323351A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-methyl-propargyl-aminoindan |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| AU1867095A (en) * | 1994-01-10 | 1995-08-01 | Technion Research & Development Foundation Ltd. | 1-aminoindan derivatives and compositions thereof |
| US5877218A (en) * | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69732984T2 (de) | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| EP1242066B1 (en) * | 1999-10-27 | 2006-06-28 | Teva Pharmaceutical Industries Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| EP2526944B1 (en) | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| CA2515200C (en) | 2003-02-06 | 2013-10-08 | University Of Georgia Research Foundation, Inc. | Galacturonosyltransferases, nucleic acids encoding same and uses therefor |
| EP1778196A4 (en) | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| CN101098685A (zh) | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| KR20140103356A (ko) | 2005-02-23 | 2014-08-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
| EP1954667B1 (en) | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| EP1991214B1 (en) | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| WO2008076315A1 (en) | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| EA016820B1 (ru) | 2006-12-14 | 2012-07-30 | Тева Фармасьютикал Индастриз, Лтд. | Кристаллическое твердое основание разагилина |
| EP1987816A1 (de) | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| EP2194780A4 (en) | 2007-09-05 | 2010-10-27 | Teva Pharma | METHOD FOR TREATING GLAUCOMA BY RASAGILINE |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| ES2389353T3 (es) | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
| JP2011522892A (ja) | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | パーキンソン病緩和のためのラサギリン |
| CA2727021A1 (en) | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| WO2009154777A2 (en) | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| RS53504B1 (sr) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | Soli razagilina i njihovi farmaceutski preparati |
| US20110130466A1 (en) | 2009-10-09 | 2011-06-02 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2939669A1 (en) * | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| EA201390613A1 (ru) | 2010-10-26 | 2013-11-29 | Тева Фармасьютикал Индастриз Лтд. | Обогащенный дейтерием расагилин |
| AU2012323351A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-methyl-propargyl-aminoindan |
| US20130089611A1 (en) | 2011-10-10 | 2013-04-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline citramide |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
-
2012
- 2012-10-09 KR KR1020147012454A patent/KR20140090996A/ko not_active Withdrawn
- 2012-10-09 JP JP2014535789A patent/JP2014534196A/ja active Pending
- 2012-10-09 EA EA201490761A patent/EA201490761A1/ru unknown
- 2012-10-09 BR BR112014008555A patent/BR112014008555A2/pt not_active IP Right Cessation
- 2012-10-09 HK HK15100235.8A patent/HK1200315A1/xx unknown
- 2012-10-09 US US13/647,685 patent/US9346746B2/en not_active Expired - Fee Related
- 2012-10-09 CN CN201280049741.8A patent/CN103874487A/zh active Pending
- 2012-10-09 AU AU2012323349A patent/AU2012323349A1/en not_active Abandoned
- 2012-10-09 MX MX2014004308A patent/MX2014004308A/es unknown
- 2012-10-09 WO PCT/US2012/059356 patent/WO2013055687A2/en not_active Ceased
- 2012-10-09 CA CA2851276A patent/CA2851276A1/en not_active Abandoned
- 2012-10-09 EP EP12839776.7A patent/EP2766002A4/en not_active Withdrawn
- 2012-10-10 AR ARP120103781A patent/AR088297A1/es unknown
-
2014
- 2014-03-26 IL IL231721A patent/IL231721A0/en unknown
- 2014-04-25 ZA ZA2014/03043A patent/ZA201403043B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534196A5 (enExample) | ||
| JP2014534197A5 (enExample) | ||
| JP7266298B2 (ja) | プリドピジンの調節放出製剤 | |
| AU2011349422B2 (en) | Novel pharmaceutical composition | |
| JP2012512907A5 (enExample) | ||
| CN104334169B (zh) | 包含氨基羧酸盐的固体组合物 | |
| CN102114011B (zh) | 一种布洛芬缓释制剂及其制备方法 | |
| CN101322695B (zh) | 双氯芬酸钾缓释胶囊及其生产工艺 | |
| CN104758265A (zh) | 一种雷诺嗪缓释片药物组合物及其制备方法 | |
| CN103610650A (zh) | 一种单硝酸异山梨酯缓释微丸及其制剂、制备方法 | |
| KR20150092385A (ko) | 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법 | |
| WO2018230504A1 (ja) | 顆粒剤、並びに錠剤及びその製造方法 | |
| Kim et al. | New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs | |
| CN104069068B (zh) | 炔丙基半胱氨酸固体分散体及其制备方法和用途 | |
| CN104706606B (zh) | 一种枸橼酸西地那非片剂及其制备方法 | |
| JP6002869B1 (ja) | ジエノゲスト含有錠剤 | |
| CN104644601B (zh) | 一种卡培他滨片剂 | |
| CN106943368A (zh) | 米氮平片剂及其制备方法 | |
| CN104586807B (zh) | 用于治疗阿尔茨海默症的缓释制剂及其制备方法 | |
| WO2011093612A2 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine | |
| CN105663071A (zh) | 一种替格瑞洛药物组合物 | |
| CN103735520B (zh) | 一种间苯三酚颗粒剂及其制备方法 | |
| Sravanthi et al. | Formulation and evaluation of bi-layer floating tablets of amlodipine besylate and metoprolol succinate | |
| CN102846574A (zh) | 一种硝苯地平控释组合物及其制备方法 | |
| Chaturvedi et al. | Comparative Evaluation Of Natural And Semisynthetic Superdisintegrants In The Formulation Of Orodispersible Tablets of Norfloxacin |